lisofylline has been researched along with transforming growth factor beta in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianco, JA; Clarke, E; Jenkins, N; Nelson, R; Rice, GC; Singer, JW; Weeks, RS | 1 |
| de Vries, P; Singer, JW | 1 |
| Bright, JJ; Sriram, S | 1 |
| Bolick, DT; Hatley, ME; Hedrick, CC; Nadler, JL; Srinivasan, S | 1 |
1 review(s) available for lisofylline and transforming growth factor beta
| Article | Year |
|---|---|
Immunotherapy of inflammatory demyelinating diseases of the central nervous system.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; CD4-Positive T-Lymphocytes; Cerebrospinal Fluid; Chlamydia Infections; Chlamydophila pneumoniae; Cytokines; Demyelinating Autoimmune Diseases, CNS; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Glatiramer Acetate; Humans; Immunotherapy; Inflammation; Interleukin-12; Mice; Multiple Sclerosis; Pentoxifylline; Peptides; Protein Kinase Inhibitors; Protein Kinases; Signal Transduction; Transforming Growth Factor beta | 2001 |
3 other study(ies) available for lisofylline and transforming growth factor beta
| Article | Year |
|---|---|
Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Division; Colony-Forming Units Assay; Drug Antagonism; Female; Fluorouracil; Hematopoiesis; Mice; Mice, Inbred BALB C; Pentoxifylline; Transforming Growth Factor beta | 1996 |
Lisofylline suppresses ex vivo release by murine spleen cells of hematopoietic inhibitors induced by cancer chemotherapeutic agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Chemokine CCL4; Cisplatin; Colony-Forming Units Assay; Culture Media, Conditioned; Cytarabine; Etoposide; Female; Growth Inhibitors; Hematopoietic Stem Cells; Macrophage Inflammatory Proteins; Melphalan; Mice; Mice, Inbred BALB C; Pentoxifylline; Spleen; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2000 |
Lisofylline, a novel antiinflammatory compound, protects mesangial cells from hyperglycemia- and angiotensin II-mediated extracellular matrix deposition.
Topics: Angiotensin II; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Connective Tissue Growth Factor; Cyclic AMP Response Element-Binding Protein; Extracellular Matrix; Extracellular Matrix Proteins; Fibronectins; Gene Expression; Glomerular Mesangium; Glucose; Humans; Hyperglycemia; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pentoxifylline; Phosphorylation; Transforming Growth Factor beta; Vasoconstrictor Agents | 2003 |